Human Metaplastic Breast Carcinoma and Decorin

Overview

Journal Cancer Microenviron

Publisher Springer

Specialty Oncology

Date 2017 Jun 28

PMID 28653173

Citations 6

Authors

Pia Bostrom

Annele Sainio

Natalja Eigeliene

Anne Jokilammi

Klaus Elenius

Ilkka Koskivuo

Hannu Jarvelainen

Affiliations

Soon will be listed here.

Abstract

Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer and has poor prognosis. In general, cancers are heterogeneous cellular masses comprised of different cell types and their extracellular matrix (ECM). However, little is known about the composition of the ECM and its constituents in MBC. Decorin is a ubiquitous ECM macromolecule known of its oncosuppressive activity. As such, it provides an intriguing molecule in the development of novel therapeutics for different malignancies such as MBC. In this study, decorin immunoreactivity and the effect of adenoviral decorin cDNA (Ad-DCN) transduction were examined in MBC. Multiple immunohistochemical stainings were used to characterize a massive breast tumour derived from an old woman. Furthermore, three-dimensional (3D) explant cultures derived from the tumour were transduced with Ad-DCN to study the effect of the transduction on the explants. The MBC tumour was shown to be completely negative for decorin immunoreactivity demonstrating that the malignant cells were not able to synthesize decorin. Ad-DCN transduction resulted in a markedly altered cytological phenotype of MBC explants by decreasing the amount of atypical cells and by inhibiting cell proliferation. The results of this study support approaches to develop new, decorin-based adjuvant therapies for MBC.

Citing Articles

In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Matossian M, Chang T, Wright M, Burks H, Elliott S, Sabol R Clin Transl Oncol. 2021; 24(1):127-144.

PMID: 34370182 PMC: 8732292. DOI: 10.1007/s12094-021-02677-8.

Down-Regulation of the Proteoglycan Decorin Fills in the Tumor-Promoting Phenotype of Ionizing Radiation-Induced Senescent Human Breast Stromal Fibroblasts.

Mavrogonatou E, Papadopoulou A, Fotopoulou A, Tsimelis S, Bassiony H, Yiacoumettis A Cancers (Basel). 2021; 13(8).

PMID: 33924197 PMC: 8074608. DOI: 10.3390/cancers13081987.

The Protective Role of Decorin in Hepatic Metastasis of Colorectal Carcinoma.

Reszegi A, Horvath Z, Karaszi K, Regos E, Postnikova V, Tatrai P Biomolecules. 2020; 10(8).

PMID: 32824864 PMC: 7465536. DOI: 10.3390/biom10081199.

Decorin Expression in Human Vulva Carcinoma: Oncosuppressive Effect of Decorin cDNA Transduction on Carcinoma Cells.

Nyman M, Jokilammi A, Bostrom P, Kurki S, Sainio A, Grenman S J Histochem Cytochem. 2019; 67(7):511-522.

PMID: 31009269 PMC: 6598130. DOI: 10.1369/0022155419845373.

iTRAQ-based proteomic analysis of DMH-induced colorectal cancer in mice reveals the expressions of β-catenin, decorin, septin-7, and S100A10 expression in 53 cases of human hereditary polyposis colorectal cancer.

Liu G, Fei F, Qu J, Wang X, Zhao Y, Li Y Clin Transl Oncol. 2018; 21(2):220-231.

PMID: 29956073 DOI: 10.1007/s12094-018-1912-6.

References

Leygue E, Snell L, Dotzlaw H, Troup S, Murphy L, Roughley P . Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol. 2000; 192(3):313-20. DOI: 10.1002/1096-9896(200011)192:3<313::AID-PATH694>3.0.CO;2-B. View

Jungmann O, Nikolovska K, Stock C, Schulz J, Eckes B, Riethmuller C . The dermatan sulfate proteoglycan decorin modulates α2β1 integrin and the vimentin intermediate filament system during collagen synthesis. PLoS One. 2012; 7(12):e50809. PMC: 3513320. DOI: 10.1371/journal.pone.0050809. View

Kaushik S, Pickup M, Weaver V . From transformation to metastasis: deconstructing the extracellular matrix in breast cancer. Cancer Metastasis Rev. 2016; 35(4):655-667. PMC: 5215979. DOI: 10.1007/s10555-016-9650-0. View

Whatcott C, Han H, Von Hoff D . Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J. 2015; 21(4):299-306. PMC: 4817719. DOI: 10.1097/PPO.0000000000000140. View

Bozoky B, Savchenko A, Guven H, Ponten F, Klein G, Szekely L . Decreased decorin expression in the tumor microenvironment. Cancer Med. 2014; 3(3):485-91. PMC: 4101739. DOI: 10.1002/cam4.231. View

Balkwill F, Capasso M, Hagemann T . The tumor microenvironment at a glance. J Cell Sci. 2013; 125(Pt 23):5591-6. DOI: 10.1242/jcs.116392. View

Walker R . The complexities of breast cancer desmoplasia. Breast Cancer Res. 2001; 3(3):143-5. PMC: 138677. DOI: 10.1186/bcr287. View

Zhu J, Goldoni S, Bix G, Owens R, McQuillan D, Reed C . Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem. 2005; 280(37):32468-79. DOI: 10.1074/jbc.M503833200. View

Li S, Chen D, Zhang W, Shen C, Che G . Prognostic value of stromal decorin expression in patients with breast cancer: a meta-analysis. J Thorac Dis. 2015; 7(11):1939-50. PMC: 4669289. DOI: 10.3978/j.issn.2072-1439.2015.11.29. View

10.

Theocharis A, Skandalis S, Gialeli C, Karamanos N . Extracellular matrix structure. Adv Drug Deliv Rev. 2015; 97:4-27. DOI: 10.1016/j.addr.2015.11.001. View

11.

Jarvinen T, Prince S . Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition. Biomed Res Int. 2015; 2015:654765. PMC: 4677162. DOI: 10.1155/2015/654765. View

12.

Bi X, Pohl N, Qian Z, Yang G, Gou Y, Guzman G . Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis. 2011; 33(2):326-30. PMC: 3271272. DOI: 10.1093/carcin/bgr293. View

13.

Andrlova H, Mastroianni J, Madl J, Kern J, Melchinger W, Dierbach H . Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget. 2017; 8(26):42901-42916. PMC: 5522114. DOI: 10.18632/oncotarget.17160. View

14.

Schaefer L, Iozzo R . Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem. 2008; 283(31):21305-9. PMC: 2490788. DOI: 10.1074/jbc.R800020200. View

15.

Chen I, Lin C, Huang C, Lien H, Hsu C, Kuo W . Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011; 130(1):345-51. DOI: 10.1007/s10549-011-1686-9. View

16.

Xing X, Gu X, Ma T, Ye H . Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. Tumour Biol. 2014; 36(3):1773-80. DOI: 10.1007/s13277-014-2779-y. View

17.

Santra M, Katakowski M, Zhang R, Zhang Z, Meng H, Jiang F . Protection of adult mouse progenitor cells and human glioma cells by de novo decorin expression in an oxygen- and glucose-deprived cell culture model system. J Cereb Blood Flow Metab. 2006; 26(10):1311-22. DOI: 10.1038/sj.jcbfm.9600285. View

18.

Rakha E, Tan P, Varga Z, Tse G, Shaaban A, Climent F . Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer. 2014; 112(2):283-9. PMC: 4453452. DOI: 10.1038/bjc.2014.592. View

19.

Lu P, Weaver V, Werb Z . The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196(4):395-406. PMC: 3283993. DOI: 10.1083/jcb.201102147. View

20.

Iozzo R, Moscatello D, McQuillan D, Eichstetter I . Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem. 1999; 274(8):4489-92. DOI: 10.1074/jbc.274.8.4489. View